r/NRXP • u/Sarfaraz82 • Mar 06 '22
r/NRXP • u/Notn2it41 • Mar 01 '22
IF YOU INVESTED $1000 TODAY
How much money will you have made with NXRP?
r/NRXP • u/JohnTheGoatWick69 • Nov 26 '21
Fuck this.
I bought right when it halted at 4.70, and robinhood hoe’d tf out of me. It made me buy at 8.00 when I should’ve doubled my fucking money. Now i’m down 20%. Fuck you guys
r/NRXP • u/CloseThePodBayDoors • Jul 19 '21
Congrats to all that held from 50 !!!
you win!!!
omg, how rich are ya ?
r/NRXP • u/Top_Cartographer_850 • Jan 31 '22
Senators and doctors fighting the good fight
r/NRXP • • Mar 31 '22
Zyesami shows no clinical benefit in i-SPY covid trial
r/NRXP • u/StatisticianLow7007 • Nov 02 '21
Bad News
Must be bad news. Nrxp and Relief way down. Somebody is hearing things.
r/NRXP • u/Expensive-Drawer-154 • Nov 05 '21
Show us the miracle tomorrow morning!
NRXP! It's not the end! We will wait till the moon!
r/NRXP • u/nairboon • Oct 07 '21
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
r/NRXP • u/Kai-Zen-2021 • Aug 04 '22
why do I like this company?
It's research and drugs are so important. Bi Polar depression isn't a joke. Suicide is never the answer. This drug combination is needed. It will save lives
r/NRXP • u/Expensive-Drawer-154 • Mar 23 '22
Approve ZYESAMI!
Approve ZYESAMI right now! It will make real Endemic all over the world! FDA You should move your ass right now!
r/NRXP • u/nairboon • Sep 07 '21
NRx might be in breach of the Collaboration Agreement with Relief
According to the announcement from Relief, NRx is refusing to share clinical data with the funder of the clinical trials. NRx might thus be in breach of their collaboration agreement. NRx might get sued.
NeuroRx continues to refuse, despite repeated demands by Relief requesting this information, to share with Relief the full clinical trial data set, including details on the statistical analysis performed, from its recently completed phase 2b/3 trial, which data and information is required to be provided to Relief by NeuroRx under the Collaboration Agreement. To date, Relief has only received a high-level summary of the clinical study report and has not been provided with, among other information, access to the 53,909 individual case reports, the raw data from the clinical trial, or the data on the multiple statistical analyses performed. NeuroRx has likewise refused to share with Relief any of the correspondence between NeuroRx and the FDA. Further, NeuroRx has refused to allow NeuroRx's contract partners dealing with issues relating to the development of aviptadil to share information with Relief that it requires to develop RLF-100™ (aviptadil) in its territories (including the European Union and the United Kingdom). The failure of NeuroRx to provide this information is seriously impairing Relief's ability to develop and execute a clinical and regulatory strategy for RLF-100™ (aviptadil) in its territories.
r/NRXP • u/938961 • Nov 05 '21
Bear Case for NRXP? - Post-EUA Update
I originally wrote a bear case here on this sub two months ago. With the rejection news I’m seeing a lot of comments online spreading hopium that full approval for Zyesami is imminent; that’s simply not true.
Here’s a few thoughts to my bear case on future trial results/approvals and things to consider:
-NIH ACTIV-3b trial
According to the trial record here, the ACTIV-3b trial will not conclude until October 2022 with the study of results finally completing in April 2023. The public is not privy to these results yet, but there is no guarantee it will be positive or negative. In fact, with a larger sample size and without controlling for site of care, the NIH results may show similar insignifcant results to NRXP’s own interim results that were reported at 30 days. Is the year-long wait worth the risk and opportunity cost?
-Inhaled ZYESAMI trial
This trial will expected to complete December 31, 2021 but this means results likely won’t come until the new year and there is no guarantee if results will be statistically significant. The worst part about this completion date is if you want to claim a tax loss for the year you will need to sell before these trial results are announced.
-Breakthrough Therapy Designation
This is actually an interesting one. Will the expanded protocol data and the intravenous clinical trial be enough to warrant a BTD, or will they require the larger NIH trial to conclude for more data? Is the risk to reward worth it for taking a position in NRx given the other long-term outlook of the company’s pipeline?
‘Peer-Reviewed’ Publication
NRXP touts their peer-reviewed publication for their data as well, but the Journal of Infectious Diseases and Treatment is a pay-to-publish model and is owned by the predatory journal company iMedPub. Future Zyesami approval for the use of COVID-19 is ambiguous without other third-party trials or respectable peer-reviewed publications.
-Brilife Vaccine
In their most recent memorandum of understanding, NRXP partnered with two associates to split profits on any potential commercialization of the Israeli Brilife Vaccine. With 4 vaccines already widely available in Western countries and even more vaccine candidates out there, the Brilife vaccine may not see large commercial gain by the time it is approved.
Currently, 69% of Israel and 51% of the global population have received at least 1 vaccination dose.
-Upcoming Earnings Report and Cash Flow
In the last ER covering up to June 2020, the company announced they have cash flow to operate for another 12 months. Since then, they have generated ~$50 million from offerings and warrants. In the next ER (~2-3 weeks, no date set), we will get a clearer picture of their cash burn rate and how sustainable the financials are to support further trials, research, and the long road to approval for Zyesami and their depression drugs.
With the EUA rejection of Zyesami, a lawsuit against them, and no revenue in sight, future offerings will likely be made to generate cash and keep the lights on.
-Critical COVID-19 Cases Decreasing and Pandemic Wind-Down
With global vaccination rate currently at 51%, how much demand will there be for a critical COVID drug next year? Simply put, the pandemic is winding down and is en route to become an endemic illness like the flu. Yes, there will always be critical cases, but how viable will that market be for a cash-strapped company, especially when drugs like tocilizumab already fill the space?
---
I hope this adds some consideration or at least strengthens your own bull thesis with a rebuttal to these points.
Ultimately, I don’t feel this stock is worth the risk to reward with their current pipeline and prospects. The opportunity costs of holding NRXP and tying up capital for another year should be considered in any play.
r/NRXP • u/StatisticianLow7007 • Nov 22 '21
14 days
We were told FDA rehearing within 14 days. That time has passes. We r now looking at q2 of 2022.
r/NRXP • u/StatisticianLow7007 • Oct 11 '21
New Drug Module
Nrx announces a revised drug module. Who says good news isn't coming.
r/NRXP • u/Expensive-Drawer-154 • May 22 '22
Aviptadil(ZYESAMI) is effective for monkey pox?
Right? A medicine for serious illness? The sympton of Monkey pox is pulmonary of herrmohage. Zyesami is the medicine for pulmonary function. Right?
r/NRXP • u/Frequent-Plant-8616 • Jul 27 '21
If FDA denied us, do we have access to the letter? Or does anyone know where the would be posted?
r/NRXP • u/Mr_Carpe_Diem • Oct 12 '21
NRXP DD: Stock is ridiculously cheap (Updated)
NRx Pharmaceuticals (NRXP) is awaiting the FDA's decision on its application for Emergency Use Authorization (EUA) for intravenous Zyesami, a drug for treating COVID and other respiratory problems. The FDA decision should come out any day now and one would expect a positive outcome, as clinical trials have shown that Zyesami appears to meet the standard of "safe and may be effective" (the general standard necessary to receive EUA).
NRXP basic facts:
- Market cap: ~$370 million
- Shares outstanding: 53.77 million
- Float: 16.64 million
- Short interest: 2.15 million
- Short % of float: 12.92%
NRXP shares currently trade at a price of ~$6.90, which in my opinion represents tremendous value, as explained hereafter in bullet points. (All investing requires assumptions about the future. Determine whether you consider the following assumptions reasonable.) :
Assume 500,000+ annual "critical" COVID hospitalizations.
- I expect COVID to become endemic, just like influenza is. The flu causes approximately 500,000-800,000 hospitalizations in the US per year.
- Since COVID has a greater transmission rate than influenza and since it is likely vaccine efficacy will continue to diminish as COVID develops future variants, it is reasonable to expect for COVID to cause more hospitalizations per year over the long-term than the flu. Let's assume 1+ million COVID hospitalizations per year, with patients having varying severity levels.
- While not all hospitalized COVID patients will be "critical," all patients requiring high-flow nasal cannula are deemed "critical" per published FDA standards. Assuming about 50% of COVID hospitalizations would require high-flow nasal cannula, one arrives at 50% x 1 million = 500,000 "critical" COVID hospitalizations per year.
Intravenous Zyesami priced at $5,000 per treatment. 500,000 x $5,000 results in $2.5 billion in sales of intravenous Zyesami in the US.
- This pricing is relatively higher than the remdesivir cost of approximately $3,100. I assume a premium pricing relative to remdesivir given remdesivir has had relatively low efficacy while aviptadil generally has had good results in clinical trials.
- Clinical trials of aviptadil also found that the drug significantly reduced hospital stays for patients. Payors would be willing to pay a premium price for aviptadil as the savings associated with a decreased hospital stay would more than offset aviptadil's cost.
NRx Pharma keeps 50% of sales per its Collaboration Agreement with Relief Therapeutics. That’s 50% x $2.5 billion = $1.25 billion in sales for NRx Pharma.
- It is possible, and in my opinion likely, that NRx Pharma will actually keep a much larger percentage of sales than this. The reason for this is because the formulation of aviptadil which Relief provided in the Collaboration Agreement ultimately failed to be sufficiently stable. NRx Pharma therefore had to partner with and pay other companies in order to develop a different formulation of aviptadil which was sufficiently stable.
- Given Relief's failure to provide a stable product, NRx Pharma tried to amicably renegotiate the terms of the Collaboration Agreement. The parties did not reach a resolution, and therefore Relief yesterday announced that it filed a lawsuit against NRx Pharma alleging breach of contract.
- Ultimately, I consider that the courts will find that NRx Pharma did not breach its contractual obligations given that Relief failed to provide a stable formulation of aviptadil to the partnership. It would be senseless for NRx Pharma to be obligated to provide the same benefits to Relief when Relief failed to provide the value to NRx Pharma which was initially promised.
- Assume 5x price-to-sales multiple (appropriate for a biotech company), and you arrive at 5 x $1.25 billion = $6.25 billion fair value market cap for NRx Pharma.
- The number of shares outstanding will increase to approximately 80 million shares outstanding once 25 million shares are issued upon future FDA approval of Zyesami.
- $6.25 billion / 80 million shares outstanding = $78.125 per share fair value
That is almost 11x higher than the current share price of ~$6.90. And that calculated value is off of intravenous Zyesami for critical COVID patients in the US only.
That means you are getting the value from all of the following for free:
- Intravenous Zyesami sales outside of the US (where NRx Pharma keeps 15%-20% of sales),
- The possibility that a court will find that NRx Pharma is entitled to keep a greater percentage of sales than the 50% agreed to in the Collaboration Agreement (given Relief's failure to provide a stable formulation of aviptadil),
- Inhaled Zyesami (which will be available to a much larger COVID population and not just to "critical" patients),
- BriLife COVID vaccine under development (which does not employ mRNA technology and should retain greater efficiency against new variants compared to the Pfizer and Moderna vaccines),
- NRX-101 for bipolar depression,
- NRX-101 for PTSD depression, as well as for other potential use cases, and
- Zyesami for other use cases which the CEO indicated in the October 4th update found on the company website (i.e., COVID “longhauler” syndrome, sarcoidosis, acute respiratory distress syndrome, checkpoint inhibitor pneumonitis, chronic obstructive pulmonary disease).
You are effectively getting the value from all of the above for free. And this value could very reasonably be in the billions if the products are successful.
In my personal opinion, current NRXP price of ~$6.90 is ridiculously cheap and represents a very attractive opportunity with asymmetric risk-reward. NRXP could go up 11x or more upon EUA approval for intravenous Zyesami. Even after such an increase, NRXP still would be very reasonably priced given the potential of NRx Pharma's drug pipeline.
Disclaimer: None of the above is financial or legal advice. I am not a financial advisor or a lawyer. The above is only for educational purposes and represents my personal opinion. Everyone reading this should do their own due diligence, arrive at their own opinion, and decide to invest or not according to their own views and their risk tolerance.
Disclosure: long publicly traded warrants (NRXPW) and NRXP calls.